Tyra’s SURF302 Data Missed the Street’s 70% CR Bar
60 mg delivered 79% ORR and clean chronic-dosing safety, but 57% CR and a new 70 mg cohort missed the Street’s bar.
Already have an account? Sign in.
60 mg delivered 79% ORR and clean chronic-dosing safety, but 57% CR and a new 70 mg cohort missed the Street’s bar.
The deal adds on-device AI to ADI’s analog chips for robots, sensors and wearables.
Barclays says Sagimet’s dermatology-first plan is smart. China data may de-risk the U.S. Phase 3 readout expected by the end of 2027.
Novartis’ DM1 trial miss hit Dyne. JPMorgan cut DYN to Underweight with a $10 target; Stifel and Jefferies stay Buy.